Division of Urology, Spectrum Health, Michigan State University, Grand Rapids, MI, USA.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Eur Urol. 2015 Dec;68(6):996-1003. doi: 10.1016/j.eururo.2015.04.043. Epub 2015 May 23.
Chronic kidney disease (CKD) can be associated with a higher risk of progression to end-stage renal disease and mortality, but the etiology of nephron loss may modify this. Previous studies suggested that CKD primarily due to surgical removal of nephrons (CKD-S) may be more stable and associated with better survival than CKD due to medical causes (CKD-M).
We addressed limitations of our previous work with comprehensive control for confounding factors, differentiation of non-renal cancer-related mortality, and longer follow-up for more discriminatory assessment of the impact of CKD-S.
DESIGN, SETTING, AND PARTICIPANTS: From 1999 to 2008, 4299 patients underwent surgery for renal cancer at a single institution. The median follow-up was 9.4 yr (7.3-11.0). The new baseline glomerular filtration rate (GFR) was defined as the highest GFR between the nadir and 42 d after surgery. Three cohorts were retrospectively evaluated: no CKD (new baseline GFR >60 ml/min/1.73 m(2)); CKD-S (new baseline GFR<60 but preoperative >60 ml/min/1.73 m(2)); and CKD-M/S (new baseline and preoperative GFR both <60 ml/min/1.73 m(2)). Cohort status was permanently set at 42 d after surgery.
Renal surgery.
Decline in renal function (50% reduction in GFR or dialysis), all-cause mortality, and non-renal cancer mortality were examined using a multivariable Cox proportional hazards model.
CKD-M/S had a higher incidence of relevant comorbidities and the new baseline GFR was lower. On multivariable analysis (controlling for age, gender, race, diabetes, hypertension, and cardiac disease), CKD-M/S had higher rates of progressive decline in renal function, all-cause mortality, and non-renal cancer mortality when compared to CKD-S and no CKD (hazard ratio [HR] 1.69-2.33, all p<0.05). All-cause mortality was modestly higher for CKD-S than for no CKD (HR 1.19, p=0.030), but renal stability and non-renal cancer mortality were similar for these groups. New baseline GFR of <45 ml/min/1.73 m(2) significantly predicted adverse outcomes. The main limitation is the retrospective design.
CKD-S is more stable than CKD-M/S and has better survival, approximating that for no CKD. However, if the new baseline GFR is <45 ml/min/1.73 m(2), the risks of functional decline and mortality increase. These findings may influence counseling for patients with localized renal cell carcinoma and higher oncologic potential when a normal contralateral kidney is present.
Survival is better for surgically induced chronic kidney disease (CKD) than for medically induced CKD, particularly if the postoperative glomerular filtration rate is ≥45 ml/min/1.73 m(2). Patients with preexisting CKD are at risk of a significant decline in kidney function after surgery, and kidney-preserving treatment should be strongly considered in such cases.
慢性肾脏病(CKD)可能与进展为终末期肾病和死亡的风险增加有关,但肾单位丢失的病因可能会改变这种情况。先前的研究表明,主要由于外科手术切除肾单位引起的 CKD(CKD-S)可能比由于医学原因引起的 CKD(CKD-M)更稳定,与更好的生存相关。
我们通过综合控制混杂因素、区分非肾性癌症相关死亡率以及更长时间的随访来解决我们之前工作中的局限性,以便更具鉴别力地评估 CKD-S 的影响。
设计、地点和参与者:1999 年至 2008 年,在一家机构接受了肾切除术的 4299 例患者。中位随访时间为 9.4 年(7.3-11.0 年)。新的基础肾小球滤过率(GFR)定义为手术与术后 42 d 之间的最低 GFR。我们回顾性评估了三个队列:无 CKD(新基础 GFR>60 ml/min/1.73 m(2));CKD-S(新基础 GFR<60 但术前>60 ml/min/1.73 m(2));以及 CKD-M/S(新基础和术前 GFR 均<60 ml/min/1.73 m(2))。队列状态在术后 42 d 时永久确定。
肾切除术。
使用多变量 Cox 比例风险模型检查肾功能下降(GFR 降低 50%或透析)、全因死亡率和非肾性癌症死亡率。
CKD-M/S 具有更高的相关合并症发生率和更低的新基础 GFR。多变量分析(控制年龄、性别、种族、糖尿病、高血压和心脏病)表明,与 CKD-S 和无 CKD 相比,CKD-M/S 肾功能进行性下降、全因死亡率和非肾性癌症死亡率的发生率更高(危险比 [HR] 1.69-2.33,均 p<0.05)。与无 CKD 相比,CKD-S 的全因死亡率略高(HR 1.19,p=0.030),但这些组的肾脏稳定性和非肾性癌症死亡率相似。新基础 GFR<45 ml/min/1.73 m(2)显著预测不良结局。主要限制是回顾性设计。
与 CKD-M/S 相比,CKD-S 更稳定,生存更好,接近无 CKD。然而,如果新基础 GFR<45 ml/min/1.73 m(2),则功能下降和死亡率的风险增加。这些发现可能会影响到存在局部肾细胞癌和更高肿瘤潜能的患者的咨询,如果存在正常的对侧肾脏。
与医学引起的 CKD 相比,手术引起的慢性肾脏病(CKD)的存活率更好,特别是如果术后肾小球滤过率≥45 ml/min/1.73 m(2)。术前患有 CKD 的患者在手术后肾功能下降的风险显著增加,在这种情况下应强烈考虑保留肾脏的治疗。